Biotech M&A Is Back. - 6/26

Forget the Lottery Tickets. Big Pharma Just Told You Where Biotech Money Is Moving. 

A quick note from Behind the Markets

Wall Street loves biotech… when it's already up 300%.

But the real money gets made earlier. When the deal tape starts moving and nobody believes it's "real" yet.

Today's Friday issue is about one thing: M&A isn't coming back. It's already here.

1) Merck's Bio-Techne deal is a tell — "picks and shovels" biotech is back in favor

Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, valuing the deal at about $11.3 billion and representing a 36% premium to Bio-Techne's one-month average price. It's Merck KGaA's biggest acquisition since it bought Sigma-Aldrich more than a decade ago.

This isn't the meme version of biotech — binary clinical trials, one drug, one datapoint, and then either heaven or hell.

Bio-Techne is the toll-booth model: research tools, diagnostic and life-science reagents, the enabling infrastructure for the whole ecosystem. (It sells over 6,000 proteins and 425,000 antibodies — the literal raw materials of drug discovery.)

Here's why this matters for independent investors. When big pharma starts paying up for "tools," it's a signal they want durable cash flows, not coin-flip science. And this isn't a one-off: Danaher bought Masimo for $9.9 billion in February, and Thermo Fisher has been reshaping its portfolio all year. The strategic buyers are writing checks — and they're prioritizing reliable revenue over lottery tickets.

The cleanest way to own that shift is the dominant toll-booth itself.

Company: Thermo Fisher Scientific (SYM: TMO)
The largest life-science tools company; instruments, reagents, and lab services used across the entire industry

Thermo Fisher is the picks-and-shovels giant — it sells the instruments, consumables, and services that every drug developer and research lab needs, regardless of which therapy ultimately wins. That's durable, recurring, "paid no matter what" revenue. Q1 2026 came in above expectations — revenue of $11 billion, up 6.2% — and management raised full-year guidance while actively reshaping the portfolio (it agreed to sell its microbiology unit for about $1.08 billion). When the sector's in favor and deal premiums are getting paid for tools businesses, the bellwether re-rates first.

TMO currently trades around $469, up roughly 19% over the past year. The honest caveat: it's a premium-quality name at roughly 26 times earnings, so it isn't cheap, and a chunk of its revenue is tied to biotech funding and academic budgets that can wobble. This is a "own the leader of a re-rating sector" idea, not a deep-value bargain. But when big pharma is validating the entire tools category with $11 billion checks, the king of that category is where durability lives.

Bottom line: This deal is the M&A canary. The next wave won't be just "new drug, new hope." It'll be companies that sell the infrastructure and get paid no matter which therapy wins.

2) The real M&A "watchlist" is not the same as your biotech watchlist

Most retail biotech lists are built wrong. They're built around the loudest chart, the hottest disease area, the next catalyst date.

That's fine if you're trading binary events. But for M&A, acquirers optimize for three things: strategic fit (fills pipeline holes, expands platforms, diversifies revenue), clean financing (they can do it without nuking their balance sheet), and integration reality (what can they absorb without breaking operations?).

So if you want to position for M&A, you tilt toward targets that are small enough to buy, big enough to matter, revenue-backed, and not toxic to integrate. A lot of the best targets are boring on purpose — and that's exactly why the Street misses them.

Here's a name that checks every one of those boxes — and just demonstrated why.

Company: Repligen (SYM: RGEN)
Pure-play bioprocessing tools — filtration, chromatography, and analytics for biologic drug manufacturing

Repligen sells the specialized hardware and consumables that biologic drugs literally cannot be manufactured without — filtration systems, chromatography columns, process analytics. It's revenue-backed (over $760 million trailing revenue), profitable, growing again (Q1 2026 revenue up 15%, with 11% organic growth and raised full-year guidance), and at roughly a $7.5 billion market cap, it sits squarely in the "big enough to matter, small enough to digest" bolt-on sweet spot that strategics like Merck, Danaher, and Thermo Fisher target. It's exactly the kind of pure-play tools asset that gets acquired in a consolidating sector.

RGEN currently trades around $130, well off its 52-week high near $176 — and it jumped roughly 11% in a single session this week as investors leaned back into the bioprocessing recovery. The honest risks: the valuation is rich (a high earnings multiple that prices in the recovery), so any stumble in biologics spending hits hard, and "takeout candidate" is a thesis, not a guarantee — you should want to own it for the business, not just the hope of a bid. But on the "think like a buyer" framework, Repligen is the textbook digestible, revenue-backed target.

Bottom line: If you're hunting M&A, stop acting like a trial-tracker. Start acting like a buyer. The winners are the targets that solve a problem and can be digested.

3) The contrarian angle: M&A can be bearish for "biotech tourists"

Here's the uncomfortable truth: when M&A returns, it does not lift every biotech stock. It usually does the opposite.

A few names get bought at big premiums. Everyone else gets repriced lower because the market stops paying for dreams.

M&A is a sorting mechanism. It says, "This company is real enough to own," and "That company is a perpetual fundraiser." And in 2026, with cost of capital still a live grenade, the second category gets punished.

So the contrarian move isn't to buy the basket of hopefuls and pray one gets a bid. It's to own the proven compounder that's doing the acquiring — the one whose entire business model is buying up the survivors and squeezing more out of them.

Company: Danaher (SYM: DHR)
Serial life-science acquirer and operator; bioprocessing, diagnostics, and genomics under a disciplined operating system

Danaher is the anti-tourist. It's a profitable, cash-generative compounder with industry-leading operating margins around 28%, and its whole playbook is acquiring quality businesses (it just bought Masimo for $9.9 billion) and improving them through its famed operating system. Over the decade ending in early 2026, the stock delivered a total return of over 450% — a masterclass in being a "real business" rather than a press-release machine. When M&A sorts the sector into haves and have-nots, Danaher is structurally on the haves side: it's the buyer, not the bought.

DHR currently trades around $212, down roughly 11% year-to-date. The honest caveats are real: some investors worry the Masimo deal is "buying revenue" to paper over a slow bioprocessing recovery (a "diworsification" risk), capital-equipment sales remain soft, China is a 10–12% revenue headwind, and at ~27x forward earnings it still isn't cheap. This is a "quality on sale, not giveaway" idea. But the entire point of this section is that M&A rewards real businesses and punishes the dreamers — and Danaher is about as "real business" as the sector gets.

Bottom line: A hot deal tape is not a sector-wide party. It's a spotlight. It exposes who has real businesses… and who just has press releases.

Before You Go

The retail edge is patience.

You don't have to guess the next datapoint.

You can build a list of high-quality targets — the kind acquirers actually want — and wait for price.